Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | TYR | P14679 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.42 |
| ▸ | NFE2L2 | Q16236 | 4/20 | 0.40 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.40 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | TTR | P02766 | 1/20 | 0.39 |
| ▸ | APP | P05067 | 1/20 | 0.39 |
| ▸ | MAP3K7 | O43318 | 2/20 | 0.39 |
| ▸ | TAB1 | Q15750 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 4/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3826433 | 1.00 | KMT2A (0.49) | KMT2AMEN1CA12CA1CA2 | |
| Hydrochloric Acid SCHEMBL7086086 | 0.98 | KMT2A (0.47) | KMT2AMEN1CA12CA1CA2 | |
| Hydrochloric Acid SCHEMBL7086087 | 0.98 | KMT2A (0.47) | KMT2AMEN1CA12CA1CA2 | |
| SCHEMBL2485956 | 0.82 | CA12 (0.46) | CA12CA1CA2CA7CA9 | |
| SCHEMBL15893 | 0.82 | CA12 (0.46) | CA12CA1CA2CA7CA9 | |
| SCHEMBL18982604 | 0.82 | LMNA (0.34) | KMT2AMEN1MAP3K7TAB1CYP2C9 | |
| SCHEMBL18982605 | 0.82 | LMNA (0.34) | KMT2AMEN1MAP3K7TAB1CYP2C9 | |
| SCHEMBL2632247 | 0.80 | MAPT (0.41) | KMT2AMEN1KDM4ESMN1; SMN2APP | |
| Cis-Urocanic Acid SCHEMBL15417 | 0.78 | KDM4E (0.43) | KMT2AMEN1CA12CA1CA2 | |
| Cis-Urocanic Acid SCHEMBL15418 | 0.78 | KDM4E (0.43) | KMT2AMEN1CA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111285433-B | CO (carbon monoxide)2Method for treating emulsified oil wastewater by atmosphere response material | 中国科学院生态环境研究中心 | 2021-09-21 | — | — | CN | claimed |
| CN-111285433-A | CO (carbon monoxide)2Method for treating emulsified oil wastewater by atmosphere response material | 中国科学院生态环境研究中心 | 2020-06-16 | — | — | CN | claimed |
| US-4500540-A | DIETETICS | HOFFMANN-LA ROCHE INC. (US) | 1985-02-19 | — | — | US | claimed |
| CN-117534866-A | Amino or amidine based porous polymer and preparation method and application thereof | 中国石油化工股份有限公司 | 2024-02-09 | — | — | CN | disclosed |
| CN-111285433-B | CO (carbon monoxide)2Method for treating emulsified oil wastewater by atmosphere response material | 中国科学院生态环境研究中心 | 2021-09-21 | — | — | CN | disclosed |
| CN-111285433-A | CO (carbon monoxide)2Method for treating emulsified oil wastewater by atmosphere response material | 中国科学院生态环境研究中心 | 2020-06-16 | — | — | CN | disclosed |
| US-20190002454-A1 | NRF2 Regulators | GLAXOSMITHKLINE IP DEV LTD (GB) | 2019-01-03 | — | — | US | disclosed |
| US-10144731-B2 | Nrf2 regulators | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-12-04 | — | — | US | disclosed |
| US-20160318917-A1 | NRF2 REGULATORS | ASTEX THERAPEUTICS LIMITED (GB) | 2016-11-03 | — | — | US | disclosed |
| EP-3083614-A1 | NRF2 REGULATORS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2016-10-26 | — | — | EP | disclosed |
| WO-2015092713-A1 | NRF2 REGULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2015-06-25 | — | — | WO | disclosed |
| WO-1999028315-A1 | IMIDAZOLE DERIVATIVES HAVING AN INHIBITORY ACTIVITY FOR FARNESYL TRANSFERASE AND PROCESS FOR PREPARATION THEREOF | LG CHEMICAL LTD. (KR) | 1999-06-10 | — | — | WO | disclosed |
| EP-0891360-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | Merck & Co., Inc. (US) | 1999-01-20 | — | — | EP | disclosed |
| US-5817677-A | ANTITHROMBOSIS AGENTS | DR. KARL THOMAE GMBH (DE) | 1998-10-06 | — | — | US | disclosed |
| WO-1998042342-A1 | THROMBIN INHIBITORS | MERCK & CO., INC. (US) | 1998-10-01 | — | — | WO | disclosed |
| WO-1997036900-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 1997-10-09 | — | — | WO | disclosed |
| US-5463071-A | Tetrazole derivatives; useful for inhibiting undesirable cell aggregation | DR. KARL THOMAE GMBH (DE) | 1995-10-31 | — | — | US | disclosed |
| EP-0525629-A2 | 5-membered heterocycles, process for their preparation and medicaments containing them | Dr. Karl Thomae GmbH (DE) | 1993-02-03 | — | — | EP | disclosed |
| US-5140034-A | Hydroxytryptamine receptor antagonists; psychological and gastrointestinal disorders | MERCK SHARP & DOHME LTD. (GB) | 1992-08-18 | — | — | US | disclosed |
| US-4931471-A | Amides of paramethoxycinnamic and utilization thereof as solar filters | UNIVERSITE LOUIS PASTEUR (FR) | 1990-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190002454-A1 | NRF2 Regulators | NFE2L2, KEAP1, NQO1 | KMT2A 1623/4885MEN1 4800/4885CA12 4870/4885 |
| US-20160318917-A1 | NRF2 REGULATORS | NFE2L2, KEAP1, NQO1 | KMT2A 1623/4885MEN1 4800/4885CA12 4870/4885 |
| US-10144731-B2 | Nrf2 regulators | NFE2L2, KEAP1, NQO1 | KMT2A 1623/4885MEN1 4800/4885CA12 4870/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.